GEP20064016B - Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof - Google Patents

Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

Info

Publication number
GEP20064016B
GEP20064016B GEAP20038766A GEAP2003008766A GEP20064016B GE P20064016 B GEP20064016 B GE P20064016B GE AP20038766 A GEAP20038766 A GE AP20038766A GE AP2003008766 A GEAP2003008766 A GE AP2003008766A GE P20064016 B GEP20064016 B GE P20064016B
Authority
GE
Georgia
Prior art keywords
methods
conjugates
preparation
uses
polymer conjugates
Prior art date
Application number
GEAP20038766A
Inventor
Alexa L Martinez
Merry R Sherman
Mark G P Saifer
L David Williams
Original Assignee
Mountain View Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US41442402P priority Critical
Priority to US10/317,092 priority patent/US20040062748A1/en
Application filed by Mountain View Pharmaceuticals filed Critical Mountain View Pharmaceuticals
Publication of GEP20064016B publication Critical patent/GEP20064016B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., polyethylene glycol and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, and use thereof.
GEAP20038766A 2002-09-30 2003-09-25 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof GEP20064016B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US41442402P true 2002-09-30 2002-09-30
US10/317,092 US20040062748A1 (en) 2002-09-30 2002-12-12 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

Publications (1)

Publication Number Publication Date
GEP20064016B true GEP20064016B (en) 2007-01-10

Family

ID=32033300

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP20038766A GEP20064016B (en) 2002-09-30 2003-09-25 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

Country Status (26)

Country Link
US (1) US20040062748A1 (en)
EP (2) EP2535347A1 (en)
JP (2) JP5366352B2 (en)
KR (1) KR101022577B1 (en)
CN (2) CN1997661B (en)
AU (1) AU2003275176B8 (en)
BR (1) BR0314831A (en)
CA (2) CA2836959C (en)
CR (1) CR7776A (en)
DK (1) DK1572728T3 (en)
EA (1) EA009122B1 (en)
EC (1) ECSP055717A (en)
ES (1) ES2504165T3 (en)
GE (1) GEP20064016B (en)
HK (1) HK1083190A1 (en)
HR (1) HRP20050353B1 (en)
IL (1) IL167723A (en)
IS (1) IS2944B (en)
MA (1) MA27521A1 (en)
MX (1) MXPA05003394A (en)
NO (1) NO20052089L (en)
NZ (1) NZ539133A (en)
PT (1) PT1572728E (en)
RS (1) RS20050263A (en)
TW (1) TWI362942B (en)
WO (1) WO2004030617A2 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
MXPA05010773A (en) 2003-04-09 2005-12-12 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods.
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
AT477020T (en) 2002-06-07 2010-08-15 Dyax Corp Prevention and reduction of ischemia
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CN102319437B (en) * 2002-12-26 2017-10-13 山景医药公司 Interferon -β having enhanced biological effectiveness of polymer conjugates
JP2006523211A (en) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド Branched water-soluble polymer and its composites
WO2004101611A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
CN1849141A (en) 2003-05-12 2006-10-18 阿费麦克斯公司 Spacer moiety for poly(ethylene glycol)-modified peptide- based compounds
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
ES2447423T3 (en) * 2003-08-29 2014-03-12 Dyax Corp. Poly-pegylated protease inhibitors
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1765853B1 (en) 2004-01-08 2015-10-28 ratiopharm GmbH O-linked glycosylation of G-CSF peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
ES2572779T3 (en) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodeling and glucopegilation of Fibroblast Growth Factor (FGF)
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US7858080B2 (en) * 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー/エス Glycopegylated factor IX
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007100829A2 (en) * 2006-02-28 2007-09-07 Dow Global Technologies Inc. Method for making polyethylene glycol carbonates
EP1997504A1 (en) * 2006-03-01 2008-12-03 Keio University Novel antithrombotic agent
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
JP5313129B2 (en) * 2006-05-02 2013-10-09 アロザイン, インコーポレイテッド Unnatural amino acid substitution polypeptide
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (en) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー/エス Method of purifying polypeptide conjugate
PT2101821E (en) 2006-12-15 2014-10-03 Baxter Int Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
BRPI0809670A8 (en) 2007-04-03 2018-12-18 Biogenerix Ag methods to increase stem cell production, to increase the number of granulocytes in an individual, to prevent, treat and alleviate myelosuppression that results from cancer therapy, to treat a condition in an individual, to treat neutropenia and thrombocytopenia in a mammal, to expand hematopoietic stem cells in culture, to increase hematopoiesis in an individual, to increase the number of hematopoietic progenitor cells in an individual, and to provide stable bone marrow graft, and, oral dosage form.
JP5876649B2 (en) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーratiopharm GmbH Improved process for producing nucleotide sugars
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
EP2195010A4 (en) * 2007-08-21 2012-03-14 Genzyme Corp Treatment with kallikrein inhibitors
EP2257311B1 (en) 2008-02-27 2014-04-16 Novo Nordisk A/S Conjugated factor viii molecules
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp Treatment of mucositis with kallikrein inhibitors
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
EP3081233A1 (en) 2009-07-27 2016-10-19 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
CA2769326A1 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
RS57870B1 (en) 2010-01-06 2018-12-31 Dyax Corp Plasma kallikrein binding proteins
AR081066A1 (en) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd It insulin conjugate where an immunoglobulin fragment is used
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP2651448B1 (en) 2010-12-13 2018-11-28 QuiaPEG Pharmaceuticals AB Water-soluble, non-peptidic, non-nucleotidic phosphoramidate functionalized polymers
BR112013015898A2 (en) 2010-12-22 2018-06-26 Baxter Healthcare Sa water soluble fatty acid derivative, and methods for preparing a fatty acid derivative and a conjugated therapeutic protein.
CN105713092B (en) 2011-01-06 2019-09-10 戴埃克斯有限公司 Blood plasma prekallikrein binding protein
JP5949037B2 (en) 2011-03-30 2016-07-06 日油株式会社 Polyoxyethylene derivatives having multiple hydroxyl groups at the ends
AU2013276219B2 (en) * 2012-06-12 2018-03-08 Quiapeg Pharmaceuticals Ab Conjugates of biologically active molecules to functionalized polymers
WO2014137161A1 (en) * 2013-03-05 2014-09-12 한미약품 주식회사 Improved preparation method for high-yield production of physiologically active polypeptide conjugate
EA201791437A1 (en) 2014-12-31 2017-12-29 Лантеус Медикал Имэджинг, Инк. Compositions of microsphere with gas distributed in lipid and related methods
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (en) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y., Us
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
IE64284B1 (en) 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JP2958019B2 (en) * 1988-05-06 1999-10-06 住友製薬株式会社 Polyethylene glycol derivatives, modified peptides, and a manufacturing method thereof
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
ZA9303926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
EP0699051A4 (en) * 1993-05-20 1998-11-25 Univ California Macromolecular contrast media for mr imaging
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
AU7113594A (en) * 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5622986A (en) * 1993-10-20 1997-04-22 Enzon, Inc. 2'-and/or 7-substituted taxanes
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AT214940T (en) 1993-11-10 2002-04-15 Enzon Inc Improved interferon-polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
CA2279986A1 (en) * 1997-02-06 1998-08-13 Claus Von Der Osten Polypeptide-polymer conjugates having added and/or removed attachment groups
WO1998048837A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6239262B1 (en) * 1998-01-07 2001-05-29 Rensselaer Polytechnic Institute Low molecular weight displacers for protein purification in hydrophobic interaction and reversed phase chromatographic systems
US5880225A (en) * 1998-02-18 1999-03-09 Arco Chemical Technology, L.P. Process for making polyetherester resins having high aromatic diester
NZ509595A (en) 1998-08-06 2004-02-27 Univ Duke Peg-urate oxidase conjugates and use thereof
CN1264575C (en) 1998-08-06 2006-07-19 山景药品公司 PEG or polyethylene oxide-urate oxidase conjugates and use thereof
AT258946T (en) 1998-08-28 2004-02-15 Gryphon Sciences A process for the preparation of polyamide chains of precise length and their conjugates with proteins
PT1121156E (en) * 1998-10-16 2006-05-31 Biogen Idec Inc Conjugates of interferro-beta-1a polymers and their uses
GB9822963D0 (en) 1998-10-20 1998-12-16 Agner Erik Improvements in or relating to chromatography
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
CN1284603C (en) 1999-10-08 2006-11-15 内科塔治疗亚拉巴马公司 Heterobifunctional poly(ethylene Glycol) derivatives and methods for their preparation
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2002080207A1 (en) 2001-03-30 2002-10-10 Arizona State University Micro-machined radio frequency switches and method of operating the same
US7229810B2 (en) * 2001-06-28 2007-06-12 Mountain View Pharmaceuticals, Inc. Polymer conjugates of proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
AU2003220917A1 (en) * 2002-03-29 2003-10-13 Daiichi Pharmaceutical Co., Ltd. Phospholipid derivative
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

Also Published As

Publication number Publication date
BR0314831A (en) 2005-08-16
IL167723A (en) 2013-01-31
CA2836959C (en) 2017-06-06
HRP20050353A2 (en) 2006-06-30
EA200500519A1 (en) 2005-12-29
CN1997661A (en) 2007-07-11
EP1572728B1 (en) 2014-06-25
CN1997661B (en) 2013-12-04
JP2006510601A (en) 2006-03-30
CA2500389C (en) 2015-03-10
CA2836959A1 (en) 2004-04-15
JP5366352B2 (en) 2013-12-11
NZ539133A (en) 2008-03-28
EP2535347A1 (en) 2012-12-19
US20040062748A1 (en) 2004-04-01
MXPA05003394A (en) 2005-10-05
CR7776A (en) 2007-10-07
EP1572728A4 (en) 2010-03-10
MA27521A1 (en) 2005-09-01
TWI362942B (en) 2012-05-01
AU2003275176A1 (en) 2004-04-23
DK1572728T3 (en) 2014-09-22
RS20050263A (en) 2007-08-03
AU2003275176B2 (en) 2008-12-18
NO20052089L (en) 2005-04-28
ES2504165T3 (en) 2014-10-08
CA2500389A1 (en) 2004-04-15
TW200416035A (en) 2004-09-01
WO2004030617A3 (en) 2005-07-21
AU2003275176B8 (en) 2009-01-08
JP2011157379A (en) 2011-08-18
EP1572728A2 (en) 2005-09-14
IS2944B (en) 2016-04-15
KR101022577B1 (en) 2011-03-16
ECSP055717A (en) 2005-08-11
KR20050083702A (en) 2005-08-26
EA009122B1 (en) 2007-10-26
WO2004030617A2 (en) 2004-04-15
JP5603823B2 (en) 2014-10-08
HRP20050353B1 (en) 2013-07-31
HK1083190A1 (en) 2015-06-19
IS7778A (en) 2005-03-30
PT1572728E (en) 2014-09-19

Similar Documents

Publication Publication Date Title
DK1572728T3 (en) Reduced antigenic polymer conjugates, manufacturing procedures and applications thereof
EP1644482B8 (en) Novel galactooligosaccharide composition and the preparation thereof
CA2578175C (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
ZA200308430B (en) Reducing the immunogenicity of fusion proteins.
AU2002302814A1 (en) Spray freeze-dried compositions
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
EP2269639A3 (en) Influenza vaccine formulations for intradermal delivery
AU2003222069A1 (en) Mammalian cdr mimetibodies, compositions, methods and uses
EP1880735A3 (en) Vaccine
AU2002341940A1 (en) Polyhydroxyalkanoate copolymer/starch compositions for laminates and films
MXPA03009042A (en) Epitope sequences.
CA2619502A1 (en) Ultra high molecular weight polyethylene articles and methods of forming ultra high molecular weight polyethylene articles
MX2010001684A (en) Compositions and methods for modifying properties of biologically active polypeptides.
MXPA04010792A (en) Calicheamicin derivative-carrier conjugates.
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
MXPA03003174A (en) SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-ggr; BINDING AGENTS.
CA2391507A1 (en) Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2003228666A1 (en) Lapachone delivery systems, compositions and uses related thereto
PT1773878E (en) Insulin-oligomer conjugates, formulations and uses thereof
EA200500475A1 (en) Water-soluble polymeric alcanals
CA2524899A1 (en) Generation of artificial binding proteins based on ubiquitin proteins
WO2004064595A3 (en) Multivalent constructs for therapeutic and diagnostic applications
AU2002354804A1 (en) Polyvalent conjugate vaccine for cancer
EP1546206A4 (en) Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
MY142354A (en) Acidic insulin preparations having improved stability